Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAPY), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Adaptimmune Therapeutics plc (ADAPY) is a biopharmaceutical company centered on engineered T-cell therapies for solid tumor cancers, and its news flow reflects this focus on oncology and cell therapy development. Company announcements highlight regulatory milestones, asset transactions, leadership changes and shifts in corporate strategy related to its cell therapy portfolio.
One key theme in Adaptimmune’s news is the evolution of its clinical assets. The company reports that the U.S. FDA approved its first biologics license application for TECELRA (afamitresgene autoleucel), described as the first engineered T-cell therapy for a solid tumor cancer approved in the United States. Subsequent news has covered the transaction through which TECELRA, lete-cel and uza-cel were acquired by US WorldMeds, as well as Adaptimmune’s role in supporting the transition of these therapies.
Another recurring topic is corporate restructuring and governance. News updates describe changes to the Board of Directors and executive leadership team, including the appointment of Chris Hill as Chief Executive Officer while he continues to serve as Chief Financial Officer. These developments are presented in the context of a broader restructuring and cost-reduction effort.
Investors and observers following ADAPY news can expect coverage of leadership changes, strategic reviews of remaining pre-clinical assets such as PRAME-directed and CD70-directed TRuC therapies, and updates on trading status, including the voluntary delisting from Nasdaq and quotation on the OTC Pink Limited Market. This news page aggregates such disclosures so readers can track how Adaptimmune’s asset base, governance and regulatory profile evolve over time.
Adaptimmune (OTC Pink: ADAPY) announced Board and executive changes effective November 14, 2025, including the appointment of Chris Hill as CEO while he continues as CFO and Director, and Lawrence Alleva as Chairman.
The company confirmed the voluntary delisting of ADSs from Nasdaq on October 28, 2025 and initiated deregistration under Section 12(b) with Form 25 and Form 15 filings; deregistration is expected around January 26, 2026. Adaptimmune said a transaction with US WorldMeds closed on July 31, 2025 to keep TECELRA available while the company focuses on maximizing value from remaining programs including PRAME and CD70.